Curr Oncol Rep. 2020 Aug 22;22(11):114. doi: 10.1007/s11912-020-00976-x.
PURPOSE OF REVIEW: Older patients with diffuse large B-cell lymphoma (DLBCL) may face challenges in treatment due to comorbidities and tolerance of chemotherapy.
RECENT FINDINGS: Older patients are at increased risk for treatment-related toxicity if they are unfit or frail by comprehensive geriatric assessment (CGA); however, treatment with non-anthracycline chemotherapy is associated with inferior outcomes in fit and unfit patients. Many older patients remain curable with standard R-CHOP chemotherapy. Careful assessment of frailty, function, and comorbidities using CGA may aid clinicians in initial therapy choices.